Objectives The breakthrough advancements in scientific medical research have greatly improved our understanding of the pathogenesis of depression, encouraging drug discoverers to take a shorter path than ever through drug repurposing to generate new antidepressant medications. In addition to reduced noradrenergic and serotonergic neurotransmission in the brain, other coincidence features such as glutamate neurotoxicity, inflammation and/or cerebrovascular insufficiency are implicated in the pathogenesis of major depressive disorder and latelife depression. This short review discusses the progress made in repurposing drugs for antidepressant actions. Key findings Drugs being repurposed as antidepressants act on novel drug targets, thereby treating resistant depression and improving remission rate. Drugs such as ketamine, dextromethorphan/quinidine and scopolamine are rapidly acting antidepressants targeting glutamate receptors. Nimodipine and quetiapine are efficient add-on therapy for late-life depression. Anti-inflammatory drugs, statins, insulin sensitizers, minocycline could remarkably contribute to treating refractory depression. Summary Drug repurposing represents an alternative approach to cope with major obstacles, including financial insufficiency and unavoidable long lag evaluation time, undermining the classical pathway of developing new hit compounds into clinically approved antidepressants.
Introduction
Major depressive disorder (MDD) has been one of the most prevalent mood disorders estimated to affect 300 million people at a global level according to World Health Organization's updated report issued in February 2017.
[1] Up to two-thirds of patients diagnosed with depressive symptoms have demonstrated insufficient response to the first-line antidepressant medications, [2, 3] highlighting the indispensable need for new antidepressant drugs preferably acting at multiple or novel targets. Depressed individuals exhibit specific symptoms such as extreme sadness, the lack of interest in daily life activity, anxiety and suicidal tendency, and it could involve interchangeable episodes of mania (bipolar depression).
[1, 4, 5] Also, cognitive dysfunction has been reported as a consequence of MDD and as depression leading cause. [6, 7] Eventually, there has been a number of depression predisposing factors including genetic and epigenetic factors. [8, 9] Late-life or vascular depression which affects old people has been found to be associated with vascular diseases and inflammation, [10] suggesting that improving blood circulation and suppressing inflammation could play a role in the treatment of vascular depression.
Several hypotheses (Figure 1 ) have been developed to explain the aetiology of MDD. Deficiency of noradrenaline (NA) and serotonin (5HT) in certain brain regions including the hippocampus and frontal cortex has been suggested for tens of years as the underlying neurobiological features of MDD and evidenced by the fact that catecholamine-depleting drugs such as reserpine induced depressive symptoms but antidepressant drugs interfering with their neuronal uptake were associated with improved mood status. [11, 12] Nevertheless, an increasing body of research work has involved other neurotransmitters such as dopamine, glutamate and gamma aminobutyric acid in the pathogenesis and treatment of MDD. [13, 14] In addition, exposure to stress accompanied with dysregulation of hypothalamic-pituitary-adrenal axis has been found to play a critical role in the development of MDD and response to antidepressant drugs. [15, 16] Increased cortisol levels were detected in biological fluids of depressed patients. [17, 18] Mifepristone, glucocorticoid receptor antagonist, has been investigated for its effects on psychiatric disorders including depression. [19] Further, melatonin receptor activation has recently been implicated in the treatment of depression. [20] For example, clinically approved antidepressant drug agomelatine stimulates G-protein-coupled melatonin receptors 1 and 2, thereby improving mood status in patients with MDD. [21] On the other hand, neurokinin receptor antagonism demonstrated antidepressant effects. [20] Neurokinins including substance P, neurokinin A and neurokinin B are excitatory neurotransmitters which exert their pharmacological actions through G-protein-coupled neurokinin 1, 2 and 3 receptors, respectively. [20] Aprepitant which blocks neurokinin 1 receptors had been found to stand as a promising antidepressant drug in early clinical studies, [22] but its week efficacy resulted in not approving it for treating MDD. [23] The neurotrophic theory has been suggested to explain why depression could develop and how antidepressant drugs improve depressed mood. [20] Markers of neuroplasticity, including brain-derived neurotrophic factor and its downstream regulator cyclic AMP response element binding protein, have been found to be implicated in rats exhibiting depression-like behaviour. [24, 25] Also, reduced expression of these proteins was reported in the hippocampus and frontal cortex of suicide victims who had been suffering from MDD. [26, 27] Obviously, the breakthrough advancements in clinical and preclinical psychopharmacological research have greatly improved our understanding of the pathological features of depression and have encouraged drug discoverers to take shorter path than ever through drug repurposing to generate new antidepressant medications. To our best knowledge, this review provides a first updated concise report addressing how such improvements in depression diagnosis have led to a considerable progress in repurposing drugs, initially approved for other therapeutic indications, for the treatment of depression.
Pathogenesis of depression: inflammation and vascular insufficiency
Advances in diagnostic methods have indicated that inflammation could contribute to the pathogenesis of depression. [18] For instance, increased levels of pro-inflammatory cytokines, such as interleukin-6 and tumour necrosis factor alpha, and high sensitivity C-reactive protein were reported in depressed patients. [28, 29] In agreement with this, anti-inflammatory drugs with different mechanisms of action have showed antidepressant effects or improved responses to the first-line antidepressant drugs as add-on therapy. [30] People with advanced age are likely to be diagnosed with late-onset or vascular depression, [10, 31] which could probably be a consequence of ongoing neurodegenerative processes such as Alzheimer's and Parkinson's diseases. [2] Poor cognitive abilities of old patients diagnosed with late-life depression or vascular depression are the most frequently reported clinical features. [32, 33] Imaging studies using magnetic resonance imaging have showed white matter lesions as hyperintensities in patients diagnosed with late-life depression (Figure 1) . [10] Vascular insufficiency accompanying ischaemia, hypertension or hypotension has been reported as predisposing factors for the development of white matter hyperintensities. [34] [35] [36] [37] [38] Likewise, chronic cerebral ischaemia produced depressionlike behaviour in rats, [39] and it was reported that atherosclerosis-related vascular insufficiency underscored the poor response to standard antidepressant drugs in patients with late-life depression. [40] In addition, inflammation biomarkers including interleukin-6, interleukin-8 and plasminogen activator inhibitor-1 have been reported to be associated with late-life depression. [41, 42] interestingly, plasminogen activator inhibitor-1 levels were found to be associated with remission of depressive symptoms. [41] It has also been under investigation to determine whether depression-related cognitive impairment could be improved by inhibiting tumour necrosis factor alpha. [6] Figure 1 Pathogenesis of depression. 5HT, serotonin; BDNF, brain-derived neurotrophic factor; CREB, cyclic AMP response element binding protein; HPA axis, hypothalamic-pituitary-adrenal axis; IL-6, interleukin-6; IL-8, interleukin-8; MDD, major depressive disorder; NA, Noradrenaline; PAI-1, plasminogen activator inhibitor-1; TNF-a, tumour necrosis factor alpha. *PAI-1 was found to be associated with remission of depression. [41] [Colour figure can be viewed at wiley
Drug repurposing: principles and techniques
Drug repurposing has been an efficient alternative drug development approach in major therapeutic areas, in particular, to generate drugs targeting psychiatric and neurological disorders. [43] Drug repurposing is cost-effective and has significantly contributed to narrow the gap between the increasing therapeutic needs and limited productivity in drug discovery. [44, 45] Drug repurposing could be in the form of repositioning, reformulation and combination. [46] Drug repositioning refers to the establishment of a new indication for a drug which has been used for other therapeutic indications; [43, 47] please refer to Figure 2 illustrating proposed new antidepressant mechanisms of action. Drug reformulation is the alteration of formulation like using the same drug but in another dosage form via the same or different route of administration. [46, 47] On the other hand, drug combination is the use of two or more drugs in combination which have been used individually to improve their efficacy and safety. [46, 48] It has been reported that around 13 drugs have been repurposed for the treatment of depression or bipolar depression, and approximately 20 antidepressant drugs have been repurposed for new indications. [43] For example, antidepressant drugs blocking 5HT 2A receptors, cyproheptadine and pizotifen, extended bleeding time in mice, and therefore, they could be repurposed as new antiplatelet drugs. [49] Moreover, selective serotonin reuptake inhibitors, widely used antidepressant drugs, such as fluoxetine have been found to have a therapeutic effect against malignancy. [50] Advanced techniques such as computational pharmacology have facilitated the process of drug repurposing. [44] Computational pharmacology could manipulate various electronic sources of huge data including genetic expression and clinical trials output accelerating repurposing studies to investigate drug target and adverse effect prediction. [44] Drugs repurposed or at the prerepurposing investigation phase for depression therapy (Table 1) The complexity of brain structure and overlapping pathological features of psychiatric disorders suggests each CNS drug could be an antidepressant candidate CNS drugs have been a rich source of repurposed drugs for psychiatric disorders. [43] Valproic acid, a well-known antiepileptic drug enhancing c-amino butyric acid neurotransmission, [51] improved effects of antidepressant drugs in patients with resistant depression. [52] Moreover, valproic acid attenuated depression-like behaviour in mice at a low dose via activating the phosphatidylinositol 3-kinase pathway, Akt phosphorylation and mammalian target of rapamycin signalling. [53] Mecamylamine, acetylcholine nicotinic receptor antagonist, had been clinically used to treat essential hypertension before being acquired for the treatment of neuropsychiatric disorders, by Targacept in 2006, [54] including resistant depression, [55] but it was discontinued in 2009. Dexmecamylamine was later developed and was reported to augment the response to citalopram in depressed patients. [56] However, dexmecamylamine failed to show such improvement in further clinical studies. [57, 58] Being resistant to the first-line antidepressant treatment, novel drug targets for vascular depression should address the underlying pathology like white matter hyperintensities. In this direction, atypical antipsychotic quetiapine, blocking 5HT 2A and dopamine D2 receptors, [59] improved pathological features including demyelination in a mouse model of vascular depression. [60] Quetiapine augmented the effects of co-administered antidepressant drugs in senior patients with MDD and cerebrovascular deterioration. [61] Drugs acting on glutamate receptors are very likely to be antidepressant Glutamate receptors have been found to be the next promising drug targets to develop new antidepressant agents. [62, 63] Ketamine, phencyclidine analogue, which has been clinically used as an intravenous non-dissociative anaesthetic drug since 1970, [64] has been recently used as an off-label antidepressant [62] and as a pain killer. [65, 66] Ketamine at low doses has been found to act rapidly and therefore especially useful for treating resistant depression. [67] Ketamine exerts its anaesthetic actions through non-competitive blockade of N-methyl-D-aspartate glutamate receptors. [68] On the other hand, ketamine metabolites hydroxynorketamines per se were found to mediate its antidepressant effects through activation of a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors, [69] paying attention to glutamate receptors as a promising drug target for developing novel rapidly acting antidepressant drugs. [63] Also, ketamine's mood improving effects have been suggested to be mediated through modulating miRNAs such as miR-598-5p and miR-451. [70] Non-coding miRNAs which regulate certain genes' expression have attracted attention as a promising drug target in the area of psychopharmacology. [62] Dextromethorphan, clinically approved cough suppressant, [71] is another example which has demonstrated antidepressant effects involving glutamatergic receptors. [72] It improved depression-like behaviour in animals [73] and patients with bipolar depression when it was combined with quinidine. [74] The formulation consisting of 20 mg of dextromethorphan and 10 mg of quinidine (Nuedexta) was approved by Food and Drug Administration (FDA) in 2011 for the treatment of pseudobulbar affective disorder, in which quinidine was added to prolong dextromethorphan's effects through inhibiting its hepatic metabolism by CYP2D6. [74] Dextromethorphan blocks N-methyl-Daspartate glutamate receptors like ketamine, and it seems to indirectly activate AMPA receptors. [75] It also affects 5HT levels through activating sigma 1 receptors, [76] thereby mediating its potential rapid antidepressant effects. [77] Despite being orally administered, giving it an Could improve its pathology AMPA, a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid; COX II, cyclooxygenase II; IL-6, interleukin-6; GABA, c-aminobutyric acid; PI3K, phosphatidylinositol 3-kinase pathway; HMG, 3-hydroxy-3-methylglutaryl; mTOR, mammalian target of rapamycin; NMDA, N-methyl-D-aspartate; PPARc, peroxisome proliferator-activated receptor gamma; TNF-a, tumour necrosis factor-alpha.
advantage over ketamine which is used mainly parenterally, [74] more clinical trials are required to validate the use of dextromethorphan for MDD and other mood disorders. It should be emphasized that ketamine being formulated as intranasal and sublingual preparations has demonstrated similar results. [63] It has been reported that scopolamine, an anticholinergic drug used for motion sickness, improved depression-like behaviour in mice through activating AMPA receptors and mammalian target of rapamycin signalling. [78] Clinical studies have also showed rapid antidepressant effects of scopolamine. [79] Experimental research revealed that N-acetyl cysteine, paracetamol antidote, possessed anxiolytic-like behaviour in zebrafish, [80] possibly through multiple mechanisms including metabotropic glutamate receptors modulation, antioxidant, anti-inflammatory and neuroprotective effects. [81] It seems important to indicate that a prior clinical study revealed that N-acetyl cysteine was ineffective as add-on therapy in improving patients' response to antidepressant drugs compared to placebo, [82] suggesting that N-acetyl cysteine could enhance patients resilience to stress, and indirectly, this may probably result in overall therapeutic outcome in depressed patients. [83] The use of drugs possessing antiinflammatory properties for depression represents a turning point in treating depression Activated inflammatory pathways have been reported to contribute to the pathogenesis of MDD, and cytokines such as tumour necrosis factor alpha was found to underlie cognitive impairment in MDD, suggesting a possible role of inflammation suppression in the treatment and remission of MDD. [6, 28] One-third of patients with MDD demonstrated a significant improvement when they were treated with potent anti-inflammatory glucocorticoid dexamethasone for 4 days. [84] Other anti-inflammatory drugs including non-steroidal anti-inflammatory drugs and anticytokines drugs have been found to relieve depressive symptoms and to enhance therapeutic effects of clinically used antidepressant drugs such as selective serotonin reuptake inhibitors. [28] For instance, selective cyclooxygenase II inhibitor celecoxib was reported to improve patients' response to sertraline, a 5HT reuptake inhibitor, apparently via decreasing IL-6 levels. [85] Also, patients who were treated with infliximab, tumour necrosis factor alpha inhibitor, showed an association between improved depressive symptoms and pretreatment increased high sensitivity C-reactive protein levels (in particular > 5 mg/l), [86] an inflammatory biomarker which has been reported to elevate in patients with resistant depression. [87] Etanercept, tumour necrosis factor alpha receptor blocker, reduced secondary depressive symptoms to some extent in patients suffering from psoriasis. [88] Also, clinical trials showed that ustekinumab, antipsoriatic anti-interleukin 12/23 monoclonal antibody, was found to improve accompanied depressive and anxious symptoms. [89] Moreover, patients treated with adalimumab, monoclonal IgG1 antitumour necrosis factor alpha antibody, for severe psoriasis had less depressive symptoms than placebo. [90] There have been increasing debates about the role of statins, cholesterol lowering drugs inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase, [91] in the treatment of MDD. [92] One study demonstrated that depressed patients treated with lovastatin in combination with fluoxetine exhibited greater improvement on Hamilton Depression Rating Scale, [4] than only fluoxetine-treated patients. [93] Other clinical studies investigating other statins showed that atorvastatin and citalopram, a 5HT reuptake inhibitor, or simvastatin and fluoxetine improved the patients' depressed mood compared to placebo groups treated with citalopram or fluoxetine, respectively. [94, 95] Statins have been reported to attenuate inflammation, oxidative distress and elevated blood lipids, thereby mediating its effects on mood disorders. [92] However, it was reported that the use of statins could rather be associated with depressive symptoms in old patients, [96] indicating that statins should be used with caution in patients with late-life or vascular depression. On the other hand, there has been a controversy about the possibility that other drugs used for metabolic disorders such as diabetes could improve depressed mood or diabetes-related cognitive impairments. [97] In particular, metformin, a widely prescribed oral antidiabetic and slimming agent, has demonstrated little promise in this regard, and therefore, large-scale studies are required before a decision concerning its repurposing could be made. [98] In contrast, clinical trials showed that insulin sensitizer antidiabetic drugs activating peroxisome proliferator-activated receptor gamma substantially reduced depressive symptoms in patients. [99] For example, pioglitazone was found to enhance remission in patients with MDD or bipolar disorders. [100] It was reported that pioglitazone mediated improvement in depressed patients probably through suppressing proinflammatory cytokines such as IL-6. [101] Moreover, neuroprotective effects have been suggested for these antidiabetic drugs. [102] Treating vascular depression through enhancing cerebral blood supply has encouraged the repurposing of vasodilators for depression therapy Given the existence of vascular insufficiency or cerebrovascular complications in old patients diagnosed with vascular depression, it could be suggested that improving cerebral blood flow by anti-ischaemic and vasodilating drugs could have a potential in eliminating underlying causes of late-life depression or may probably improve the effectiveness of standard antidepressant treatment. [103, 104] For example, calcium channel blocker nimodipine, which had been approved by FDA for neurological complications of cerebrovascular diseases, improved the therapeutic effects of antidepressant drugs in old patients with vascular depression, [105] and enhanced the depression remission rate in fluoxetine-treated patients diagnosed with vascular depression. [106] Balanced diets and intake of supplements have been found to counteract vascular depression. It was reported that high doses of vitamin D3 improved vascular depression through effects on cardiovascular complications in geriatric patients undergoing renal dialysis. [107] Developing or repurposing a new antidepressant with multiple drug targets could be the solution Generally, it has been believed that novel antidepressant drugs acting on multiple targets outperform the current first-line antidepressant drugs through exerting rapid and higher therapeutic response and remission rate. Vortioxetine, one of the recently marketed antidepressant drugs, which was approved by FDA in 2013 for the treatment of MDD, [108] is a polypharmacology drug. Vortioxetine acts on multiple targets by inhibiting neuronal serotonin uptake, blocking 5HT 3 , 5HT 7 and 5HT 1D receptors and activating 5HT 1A receptors. [108] Vortioxetine could also be effective in the treatment of vascular depression and related cognitive dysfunction. [109] Interestingly, tetracycline antibiotic minocycline, which has been reported to possess neuroprotective and anti-inflammatory effects, [110, 111] promoted effects of antidepressant drugs. [112] 
Conclusion
Despite the availability of apparently sufficient antidepressant drugs in the market, there is still a considerable distance away from meeting the actual needs, given the delay of their mood elevating effects and the lack of satisfactory response in increasing number of patients with refractory depression. Drug repurposing emerges as an alternative cost-effective approach which could accelerate the generation of new antidepressant drugs (repositioning) or co-antidepressant medication (combination), maximizing the overall therapeutic outcome and the rate of remission.
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